National survey of low-threshold structures (CAARUDs)
Conducted every two years since 2006 in all CAARUDs (Support Centre for the Reduction of Drug-related Harms) on mainland France and in French overseas departments, this survey determines the number of users seen in these structures, the characteristics of these users and their use patterns. Each user who enters into contact with the structure during the survey undergoes a face-to-face interview with someone working at the structure. The questions asked are on use (frequency, age of experimentation, administration route), use-related behaviour (injection, equipment-sharing), screening (HIV, HBV and HCV) and social situation (social coverage, housing, level of education, support from friends and family).
The 2012 survey was conducted from 26 November to 7 December: 4,241 completed or "non-responder" questionnaires were conducted in 142 CAARUDs. After eliminating duplicates (299) and "non-responders" (1,037), 2,905 individuals (in 139 CAARUDs) were included in the analysis.
CAARUD client profiles and practices in 2012
Tendances n° 98, January 2015
CAARUD: client profiles and practices in 2008
Tendances n° 74, December 2010
The first national survey on users of the CAARUD centres
Tendances N° 61, May 2008
Drugs in Europe
- Drug facts, figures and analyses: across Europe and by country
- Latest trends and legal, political and social responses
- Selected issues: Vulnerable groups of young people; National drug-related research in Europe; Towards a better understanding of drug-related public expenditure in Europe
Country situation summaries
The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) website has a concise overview for each EU Member State on their national drug situation, as well as legal texts in their original formats, an indispensable tool for monitoring and analysing legislative developments in the Member States.
The European Union and the drug phenomenon
The European Union & the drug phenomenon : Frequently asked questions , joint publication between the EMCDDA and the European Commission, october 2010, 12 p.